Trial document



drksid header

  DRKS00003551

Trial Description

start of 1:1-Block title

Title

graft function adapted tacrolimus therapy after liver transplantation (GRAFTT)

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

GRAFTT

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

http://www.charite.de/avt/forschung/workgroup_for_the_liver/ongoing-projects.html#GRAFTT

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

Tacrolimus is an important standard induction and maintenance immunosuppressant drug after liver transplantation (LT). Nevertheless, tacrolimus has a narrow therapeutic window and can cause serious adverse effects. Acute overdosing can provoke renal failure and severe neurological disorders, On the other hand, insufficient levels could lead to graft rejection in the initial post-transplant phase.
The purpose of the study is to improve immunosuppressive therapy until three days after liver transplantation.

Patients receiving primary orthotopic LT will be enrolled in this study.
The aim of this study is to achieve a reduced number of patients suffering from toxic drug reactions or organ rejection.

Our assumption is that medication adaption for real liver function improves graft survival.

Therefore the real liver function is measured after liver transplantation. The dosage of tacrolimus will be adapted on this measured liver function. The measument will be repeated on first day after liver transplantation.




end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

Prospective,randomized, controlled open label trial with Prograf® and Advagraf® (GRAFTT)

end of 1:1-Block scientific synopsis
start of 1:1-Block forwarded Data

Do you plan to share individual participant data with other researchers?

[---]*

end of 1:1-Block forwarded Data
start of 1:1-Block forwarded Data Content

Description IPD sharing plan:

[---]*

end of 1:1-Block forwarded Data Content
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00003551
  •   2013/05/31
  •   2011/12/05
  •   yes
  •   Approved
  •   11/0560-ZS EK 11, Ethik-Kommission des Landes Berlin
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   2011-004944-23 
  •   EUCTR2011-004944-23-DE  (EUCTR)
  •   4037842 
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   livertransplantation
  •   K72.9 -  Hepatic failure, unspecified
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Prograf®, with liver function adapted TAC-regime in the first three days after LTx, twice a day, 0,025- 0,1 mg/kg body weight
  •   Advagraf®, with liver fuction adapted TAC-regime, in the first three days after LTx, once a day, 0,05- 0,2 mg/kg body weight

  •   control group with standard tacrolimus regime (Prograf), in the first three days after LTx, twice a day, 0,05 mg/kg body weight

end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Interventional
  •   [---]*
  •   Randomized controlled trial
  •   Open (masking not used)
  •   [---]*
  •   Active control
  •   Treatment
  •   Parallel
  •   IV
  •   No
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Number of patients suffering from either toxic or insufficient tacrolimus whole blood trough levels during the initial 14 days after liver transplantation
(twice levels of <5 ng/mL during post-transplant days 1-14 or one levels >20 ng/mL during post-transplant days 1-14)

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

1.) Tacrolimus whole blood trough level during post-transplant days 1-14

2.) Total cumulative incidence of inadequate tacrolimus whole blood trough levels during post-transplant days 1-14 (<5 ng/mL or >20 ng/mL)

3.) Creatinine serum levels (day 1-14 after transplantation)

4.) Incidence of Adverse effects:
a.) acute renal failure (days 1-14)
b.) chronic renal insufficiency (until 1 year after transplantation)
c) Neurological effects including
encephalopathy, seizures or coma (days 1- 14)
5.) graft rejection (time frame: 1 year)
6.) Rejection free time interval (time frame: 1 year)
7.) Assessment of graft and patient survival (time frame: 1 year)

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • University Medical Center 
  • University Medical Center 
  • University Medical Center 
  • University Medical Center 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Actual
  •   2012/07/26
  •   210
  •   Multicenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

Inclusion criteria
-Patients intended for orthotopic deceased-
donor LT
- Recipient age ≥18 yrs.
- Capability to understand the purpose and
the risk of the study
- Written informed consent prior LT

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

- Participation in other clinical trials during <28 days before LT
- any organ transplantation before enrollment, High-urgent transplantation, split liver LT, living donor LT, combined multi-organ transplantation, AB0 incompatible grafts, retransplantation
- Recipients with malignant tumors beside HCC respecting the Milan criteria or liver metastasis
-Target trough levels of tacrolimus differing from 10-15 ng/mL in the first 14 days after LTx)
- planned use of other immunosuppressive drugs including ciclosporine A, sirolimus, everolimus, azathioprine in the first 14 days after LTx

- patients with known intolerance of tacrolimus
- patients with a history of substance or drug abuse
- patients with psychiatric disorders or any forms of substance abuse not capable of understanding the purpose and risks of the study
- subjects known to be HIV positive- pregnant woman or breastfeeding mother

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Charité Universitätsmedizin Berlin
    • Augustenburger Platz 1
    • 13353  Berlin
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Charité Campus Virchow-Klinikum
    • Mr.  Priv.-Doz.  Martin  Stockmann 
    • Augustenburger Platz 1
    • 13353  Berlin
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Charité Universitätsmedizin Berlin
    • Priv.-Doz.  Martin  Stockmann 
    • Augustenburger Platz 1
    • 13353  Berlin
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Charité Campus Virchow-Klinikum
    • Augustenburger Platz 1
    • 13353  Berlin
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    end of 1:1-Block address contact materialSupport
  • start of 1:1-Block address otherSupport
    • Astellas Pharma GmbH
    • Georg-Brauchle- Ring
    • 80992  München
    • Germany
    end of 1:1-Block address otherSupport
    start of 1:1-Block address contact otherSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact otherSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting ongoing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.